- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03495063
Synthetic and Natural Caffeine on Hemodynamic Parameters in Young, Healthy Volunteers
Comparison of Synthetic and Natural Caffeine on Hemodynamic Parameters in Young, Healthy Volunteers: A Randomized, Double Blind, Crossover Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to assess the difference in effects of consuming synthetic versus natural caffeine on hemodynamic parameters in healthy subjects. This study will determine the difference in hemodynamic effects of synthetic and natural caffeine consumption in healthy individuals through blood pressure (central and peripheral) assessment. The participants in this study are healthy adults who will be introduced to a risk that may be more than they would encounter through their normal daily activities. This study seeks to add to the literature by evaluating the difference in impact of synthetic compared to natural caffeine on central blood pressure.
This protocol has the following aims:
- Investigators hypothesize there will be a (baseline adjusted [ΔBP]) difference in BP (peripheral and central) between the natural and synthetic caffeine arms in healthy volunteers post consumption.
- Investigators hypothesize there will be (baseline adjusted [ΔCO]) no difference in CO between the natural and synthetic caffeine arms in healthy volunteers post consumption.
- Investigators hypothesize there will be (baseline adjusted [ΔSVR]) no difference in SVR between the natural and synthetic caffeine arms in healthy volunteers hours post consumption.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Travis Air Force Base, California, United States, 94535
- David Grant Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females
- Active duty military service members
- DoD beneficiaries
- Participants must be willing to refrain from caffeine use 72 hours prior to study days one and five
Exclusion Criteria:
- Cardiovascular risk factors: Heart rhythm other than normal sinus, history of atrial or ventricular arrhythmia, family history of premature sudden cardiac death before the age of 60, left ventricular hypertrophy, acute myocardial ischemia, atherosclerosis, hypertension, and palpitations. This will be determined through the questionnaire responses of the participant and thorough chart review.
- Blood pressure at initial screening appointment or at baseline on study Day One greater than 130/80 and if 130-139/80-89, FRS risk greater than 10%.
- Presence of any known medical condition, confirmed through participant interview up to the discretion of the research team. Examples of these are:
- Hypertension
- Thyroid disease
- Type 1 or 2 Diabetes Mellitus
- Recurrent headaches
- Any psychiatric condition or neurological disorder including seizures
- History of alcohol or drug abuse in the previous five years
- Ever been diagnosed or told they have or had renal or hepatic dysfunction
- Tobacco use
- Concurrent use of any medication taken in an amount greater than twice a week, to include herbal products or supplements, not to include hormonal contraceptives. If less than or equal to two days per week, the investigator will determine if the subject is to be included or excluded based on the available literature for that medication.
- Pregnant or lactating females will be excluded from participation with urine dipstick tests used to rule out pregnancy (pregnancy test performed before each treatment session, days one, five)
- All non-English speaking/writing subjects and those that do not understand the study or consent process will be excluded from the study due to unavailability of medical qualified translator at all times during the study.
- If the subject refuses to sign the informed consent document or HIPAA Authorization, they will be excluded as well.
- Allergy to any substance in the study design.
- Any other medical reason that at the discretion of the investigators would pose a risk to the health of the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Natural Caffeine
Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine.
Blood pressure measurements will be taken at baseline, then hourly for four hours.
|
Consumption of 400mg of natural caffeine
|
Experimental: Synthetic Caffeine
Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine.
Blood pressure measurements will be taken at baseline, then hourly for four hours.
|
Consumption of 400mg of synthetic caffeine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral systolic blood pressure
Time Frame: Four hours
|
Two peripheral systolic blood pressure measurements will be taken prior to the consumption of the assigned study drink.
Repeated peripheral systolic blood pressure readings will occur twice at each time point hourly for a period of four hours.
For each measurement, participant will be asked to rest for five minutes.
|
Four hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in peripheral diastolic blood pressure
Time Frame: Four hours
|
Two peripheral diastolic blood pressure measurements will be taken prior to the consumption of the assigned study drink.
Repeated peripheral diastolic blood pressure readings will occur twice at each time point hourly for a period of four hours.
For each measurement, participant will be asked to rest for five minutes.
|
Four hours
|
Cardiac output
Time Frame: Four hours
|
Cardiac output will be measured prior to the consumption of assigned study drink.
Repeated cardiac output readings will occur twice at each time point hourly for a period of four hours.
For each measurement, participant will be asked to rest for five minutes.
|
Four hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elizabeth A Tesch, David Grant Medical Center
- Principal Investigator: Sachin A Shah, David Grant Medical Center
Publications and helpful links
General Publications
- Fletcher EA, Lacey CS, Aaron M, Kolasa M, Occiano A, Shah SA. Randomized Controlled Trial of High-Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. J Am Heart Assoc. 2017 Apr 26;6(5):e004448. doi: 10.1161/JAHA.116.004448.
- Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008 Aug 28;359(9):938-49. doi: 10.1056/NEJMra0801082. No abstract available.
- Guessous I, Eap CB, Bochud M. Blood pressure in relation to coffee and caffeine consumption. Curr Hypertens Rep. 2014 Sep;16(9):468. doi: 10.1007/s11906-014-0468-2.
- Hartley TR, Lovallo WR, Whitsett TL. Cardiovascular effects of caffeine in men and women. Am J Cardiol. 2004 Apr 15;93(8):1022-6. doi: 10.1016/j.amjcard.2003.12.057.
- Knapik JJ, Trone DW, McGraw S, Steelman RA, Austin KG, Lieberman HR. Caffeine Use among Active Duty Navy and Marine Corps Personnel. Nutrients. 2016 Oct 9;8(10):620. doi: 10.3390/nu8100620.
- Lieberman HR, Stavinoha T, McGraw S, White A, Hadden L, Marriott BP. Caffeine use among active duty US Army soldiers. J Acad Nutr Diet. 2012 Jun;112(6):902-12, 912.e1-4. doi: 10.1016/j.jand.2012.02.001.
- Marik PE. Noninvasive cardiac output monitors: a state-of the-art review. J Cardiothorac Vasc Anesth. 2013 Feb;27(1):121-34. doi: 10.1053/j.jvca.2012.03.022. Epub 2012 May 19. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDG20180007H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Injury
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Radboud University Medical CenterPfizerCompletedCardiovascular Disease | Ischemia Reperfusion InjuryNetherlands
-
Radboud University Medical CenterCompletedCardiovascular Disease | Ischemia-Reperfusion InjuryNetherlands
-
Centre Hospitalier Universitaire de NiceCompletedLiver Injury | Pseudoaneurysm | Hepatic InjuryFrance
-
University of AarhusErasmus Medical Center; Fonden til Lægevidenskabens FremmeCompletedIschemia Reperfusion Injury | Ischaemia Reperfusion InjuryDenmark
-
Health Effects InstituteUniversity of California, San Francisco; University of North Carolina, Chapel... and other collaboratorsUnknown
-
University of Colorado, DenverTerminatedLiver Transplantation | Ischemia/Reperfusion Injury | Oxidative InjuryUnited States
-
Radboud University Medical CenterWithdrawnCardiovascular Disease | Ischemia-reperfusion Injury | PostconditioningNetherlands
-
Methodist Health SystemEnrolling by invitation
-
Qin ZhangRecruiting
Clinical Trials on Natural Caffeine
-
Sprim Advanced Life SciencesArtsana S.p.a.CompletedFeeding Behavior
-
Wenxiang WangShanghai Houchao Biotechnology Co., LtdUnknownNon-small Cell Lung CancerChina
-
Hampton VA Medical CenterCompletedPersonality Disorders | Depression | Bipolar Disorder | Substance Use Disorders | PsychosisUnited States
-
Alpha - Bio Tec Ltd.Unknown
-
Acibadem UniversityUnknownInfertility, FemaleTurkey
-
Alcon ResearchCompleted
-
Pennington Biomedical Research CenterOhio State UniversityCompleted
-
Emily de los ReyesRecruitingBatten Disease | CLN6United States
-
Virginia Commonwealth UniversityUniversity of Western Ontario, Canada, Children's Health Research Institute; Fondazione Serena Onlus - Centro Clinico NeMO MilanoRecruitingCongenital Myotonic DystrophyUnited States, Italy, Canada
-
Ludwig-Maximilians - University of MunichCompletedInclusion Body Myositis, Sporadic | Inclusion Body Myopathy, Autosomal-recessive | Inclusion Body Myopathy, Autosomal-dominant | Congenital Cataracts, Facial Dysmorphism, And NeuropathyGermany